| Literature DB >> 27929511 |
Nnamdi N Jibiri1, Christopher J Olowookere.
Abstract
In Nigeria, a large number of radiographic examinations are conducted yearly for various diagnostic purposes. However, most examinations carried out do not have records of doses received by the patients, and the employed exposure parameters used are not documented; therefore, adequate radiation dose management is hin-dered. The aim of the present study was to estimate the dose-area product (DAP) of patients examined in Nigeria, and to propose regional reference dose levels for nine common examinations (chest PA, abdomen AP, pelvis AP, lumbar AP, skull AP, leg AP, knee AP, hand AP, and thigh AP) undertaken in Nigeria. Measurement of entrance surface dose (ESD) was carried out using thermoluminescent dosimeter (TLD). Measured ESDS were converted into DAP using the beam area of patients in 12 purposely selected hospitals. Results of the study show that the maximum/ minimum ratio ranged from 3 for thigh AP to 57 in abdomen AP. The range of determined mean and 75th percentile DAPs were 0.18-17.16, and 0.25-28.59 Gy cm2, respectively. Data available for comparison show that 75th percentile DAPs in this study (in chest PA, abdomen AP, pelvis AP, lumbar AP) are higher than NRPB-HPE reference values. The DAP in this study is higher by factor of 31.4 (chest PA), 9.9 (abdomen AP), 2.2 (pelvis AP), and 2.1 (lumbar AP) than NRPB-HPE values. The relative higher dose found in this study shows nonoptimization of practice in Nigeria. It is expected that regular dose auditing and dose optimization implementation in Nigeria would lead to lower DAP value, especially in abdomen AP. The 75th percentile DAP distribution reported in this study could be taken as regional diagnostic reference level in the Southwestern Nigeria; however, a more extensive nationwide dose survey is required to establish national reference dose.Entities:
Mesh:
Year: 2016 PMID: 27929511 PMCID: PMC5690520 DOI: 10.1120/jacmp.v17i6.6011
Source DB: PubMed Journal: J Appl Clin Med Phys ISSN: 1526-9914 Impact factor: 2.102
Specific features of X‐ray units investigated (output and exposure rate measured at distance of 1 m and tube potential of 80 kV)
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| FMC | Ralco | ‐/2013 | 2.0 | 0.3859 | 0.5267 |
| EKSUTH | Allenger 40 | 2012/‐ | 0.9 | 0.3892 | 0.4471 |
| OAGSH | Picker | ‐/2013 | 2.5 | ‐ | ‐ |
| FKJSH | Generic | 2007/2009 | 2.0 | ‐ | ‐ |
| ALSH 1 | Generic | 2007/2009 | 2.0 | 0.4531 | 0.4467 |
| ALSH 2 | Siemens Mobile MiniX‐ray | 2013/2013 | 2.2 | ‐ | ‐ |
| TTPC 1 | Allenger 525 | 2007/‐ | 0.9 | 0.2069 | 0.7633 |
| TTPC 2 | Allenger 525 | 2007/‐ | 0.9 | 0.3998 | ‐ |
| VHS | Acoma Japan | 1983/‐ | ‐ | ‐ | ‐ |
| LTH 1 | Neo Diagnomax | 1982/‐ | 3.0 | 0.1825 | 0.3246 |
| LTH 2 | Allenger 40 | 2009/ | 1.5 | 0.2889 | 2.1083 |
| SDAH | – | 2009/2011 | 2.5 | 0.1938 | 0.8538 |
| OAUTHW | Siemens | 2007/‐ | 2.7 | 0.6102 | 3.500 |
| ANHS | Ralco | ‐/2013 | 2.2 | 0.3064 | 0.1722 |
| AYHS | GEC Medical | 1974/‐ | 3.0 | 0.02146 | 0.1158 |
Patient information and statistical parameters of DAP (Gy cm2) distribution among the hospitals
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| Chest PA | 306 | 67 (37–120) | 44.2 (17–90) | 3.06 (0.19) | 1.01–39.38 | 1.15 | 3.14 | 39 |
| Abdo AP | 20 | 68 (40–91) | 58.7 (31–80) | 17.16 (4.96) | 1.21–68.61 | 7.21 | 28.59 | 57 |
| Pelvis AP | 35 | 73 (54–98) | 47.9 (19–74) | 3.28 (0.47) | 1.07–12.51 | 2.44 | 4.77 | 12 |
| Lumbar AP | 87 | 71 (46–105) | 51.1 (20–76) | 2.72 (0.44) | 1.04–24.12 | 1.40 | 3.20 | 23 |
| Skull AP | 32 | 65 (48–77) | 42.9 (19–80) | 4.53 (0.052) | 0.63–31.79 | 2.31 | 5.06 | 51 |
| Leg AP | 46 | 69 (40–99) | 39.1 (16–82) | 1.14 (0.15) | 0.057–3.05 | 0.93 | 2.04 | 54 |
| Knee AP | 17 | 71 (63–87) | 57.2 (26–82) | 1.53 (0.21) | 0.11–3.00 | 1.89 | 2.09 | 27 |
| Hand AP | 45 | 64 (40–100) | 42.7 (19–90) | 0.92 (0.14) | 0.21–2.85 | 0.43 | 1.44 | 14 |
| Thigh AP | 12 | 72 (56–80) | 30.6 (28–46) | 0.27 (0.008) | 0.11–0.31 | 0.23 | 0.25 | 3 |
Figure 1Values of DAP as against the distribution of dose for different procedures (chest, lumbar, pelvis, and skull); arrows indicate 10th and 75th percentiles of the dose distributions.
Range of mean exposure parameter among different health–care centers investigated
|
| ||||
|---|---|---|---|---|
|
|
|
|
|
|
| Chest PA | 15 | 62–97 | 8–51 | 84–173 |
| Abdomen AP | 6 | 78–110 | 26–100 | 69–91 |
| Pelvis AP | 7 | 65–87 | 18–64 | 81–111 |
| Lumbar AP | 12 | 65–107 | 23–117 | 64–122 |
| Skull AP | 8 | 69–88 | 15–78 | 64–137 |
| Leg AP | 8 | 48–102 | 4–80 | 60–160 |
| Knee AP | 12 | 49–67 | 5–32 | 71–108 |
| Hand AP | 6 | 50–53 | 4–30 | 48–97 |
| Thigh AP | 3 | 56–78 | 10–50 | 82–124 |
Comparison of average exposure factors and mAs setting with others used elsewhere (adult)
|
|
|
|
|
|
|
|
| |||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||||
| Chest PA | 75 (55–185) | 25.9 (0.33–100) | 125.3 (42–185) | 22.4 (16.8–33.9) | 88 | 5 | 120 | – | 77 | 12 |
| Abdomen AP | 86 (75–117) | 58.1 (20–125) | 82.3 (68–99) | 22.4 (17.2–25.4) | 76 | 41 | 75 | – | – | – |
| Pelvis AP | 78 (52–92) | 35.7 (5–75) | 91.9 (63–137) | 23.3 (19.9–26.9) | 75 | 33 | 75 | – | – | – |
| Lumbar AP | 85 (60–117) | 62.8 (9–200) | 76.8 (40–160) | 23.2 (19.3–28.7) | 78 | 46 | 75 | 10.3 | 70 | 84 |
| Skull AP | 75 (60–85) | 44.4 (8–125) | 77.6 (56–122) | 22.0 (19.7–24.4) | 72 | 20 | 80 | – | 66 | 59 |
| Leg AP | 62 (48–102) | 18.7 (3.2–80) | 82.4 (60–160) | 12.3 | – | – | 70 | 10 | – | – |
| Knee AP | 63 (58–80) | 9.2 (5–32) | 87.8 (65–108) | 13.5 | – | – | 70 | 12 | – | – |
| Hand AP | 57 (40–94) | 9.2 (2.5–32) | 78.8 (52–107) | 8.6 | – | – | 60 | 4 | – | – |
| Thigh AP | 66 (56–75) | 17.4 (10–25) | 103.3 (82–124) | 23.1 (21.5–23.6) | – | – | – | – | – | – |
Hart et al.
Gkanatsios and Huda.
Freitas and Yoshimura.
Measured with a tape.
Effective doses (mSv) estimated from DAP (Gy cm2) for various procedures and patient sizes of male and female adults
|
|
|
|
|
|
|---|---|---|---|---|
| Chest PA | 156 (m) | 0.44 (0.0052–5.34) | 22.85 | 22.16 |
| 150 (f) | 0.39 (0.0012–0.41) | 25.66 | 22.71 | |
| Abdo AP | 10 (m) | 0.89 (0.14–2.93) | 23.23 | 21.74 |
| 10 (f) | 2.56 (0.18–7.28) | 24.18 | 23.15 | |
| Pelvis AP | 21 (m) | 0.78 (0.078– 2.20) | 23.25 | 22.56 |
| 14 (f) | 0.20 (0.12–0.39) | 29.71 | 24.68 | |
| Lumbar AP | 48 (m) | 0.84 (0.0087–5.86) | 24.33 | 22.28 |
| 39 (f) | 0.46 (0.0015–1.69) | 26.36 | 23.09 | |
| Skull AP | 21 (m) | 0.16 (0.021–0.96) | 21.77 | 21.81 |
| 11 (f) | 0.078 (0.019–0.24) | 21.91 | 22.55 | |
| 30 (m) | — | 25.07 | 11.42 | |
| Leg AP | 16 (f) | — | 28.42 | 13.92 |
| 35 (m) | — | 21.67 | 8.87 | |
| Hand AP | 10 (f) | — | 19.75 | 6.21 |
Thickness of irradiated part measured with ruler, and the corresponding BMI calculated from height and weight.
Dose–area product, DAP (Gy cm2), and the equivalent effective doses (mSv) estimated for different procedures for all patients (both male and female)
|
|
|
|
|---|---|---|
| Chest PA | 3.06 | 0.42 |
| Abdomen AP | 17.16 | 1.82 |
| Pelvis AP | 3.28 | 0.52 |
| Lumbar AP | 2.72 | 0.66 |
| Skull AP | 4.53 | 0.14 |
| Thigh AP | 0.27 | 0.020 |
Comparison of DAP (Gy cm2) in this study with values determined elsewhere (NRPB–HPA, Nigeria, and Iran)
|
| |||||
|---|---|---|---|---|---|
|
|
|
|
|
|
|
| Chest PA | 3.06 | 3.14 | 0.1 | 1.25 | 0.22 |
| Abdomen AP | 17.16 | 28.59 | 2.9 | 0.56 | 1.29 |
| Pelvis AP | 3.28 | 4.77 | 2.2 | 0.46 | 1.11 |
| Lumbar AP | 2.72 | 3.20 | 1.5 | – | 0.71 |
| Skull AP | 4.53 | 5.06 | – | 0.34 | 0.42 |
| Leg AP | 1.14 | 2.04 | – | – | – |
| Hand AP | 0.92 | 1.44 | – | – | – |
Akinlade et al.
Shandiz et al.